Molecule to Market: Inside the outsourcing space

The life science dating agent

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Martino Picardo, Chairman at Discovery Park.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Martino, covering:

• His ‘three careers’ over the last few decades, mainly spent translating science into commercial entities that make a difference.
• Building Stevenage Bioscience Catalyst from the ground-up from the middle of the golden triangle through relationships, partnerships and networking.
• The ‘holy trilogy’ of building incubators from a blank sheet to successful, thriving communities.
• Creating a life science village from a transitioning Pfizer R&D site in the UK into an ecosystem with 160 companies.
• Never being a better time to work in life sciences and for entrepreneurs to thrive in the ecosystem.

Martino is Chairman of Discovery Park and an Independent Consultant. With a a PhD in Biochemistry, Martino spent almost a decade with Amersham International after his time in academia.

He was the first CEO of the Stevenage Bioscience

Catalyst an ambitious concept to develop an Incubator and Accelerator, which is now as world class Science Park.

A former Entrepreneur in Residence at UMIP, Manchester and with the NHS, Martino is also on Board of BIONOW, and is Chairman of VisusNano Ltd and Evidential Ltd.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

A little, big announcement...

After years of frustration with recruitment service providers in our space and seeing many of my CRO/CDMO connections miss their growth targets because their talent agenda just can’t keep up, I decided to create a talent sourcing solution for pharma & bio outsourcing. Proudly introducing, Lead Candidate.

The business has been founded purely to support ambitious, growing CROs, CDMOs and pharma service firms. Lead Candidate aims to help address many of the common issues we see guests talk about - attracting people into industry, improving diversity in our sector and simply being better prepared for growth.

For many years, I strongly believed there was a need for long-term, responsible, talent acquisition from people who genuinely understand the intricacies of our industry. And a firm that would also take responsibility for championing careers and treating people with respect. 

Whether you’re looking to build your team or find your next move, visit Lead Candidate and get in touch with the team.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The CDMO start-up... with a heck of a track record

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug product and sterile injectables sector with Cory Lewis CEO and President, Founder at INCOG BioPharma Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Cory, covering:

• The incredible 10-year journey of Cook Pharmica from a burning cash turnaround challenge to a $950M acquisition by Catalent.
• Customer-centric lessons learned from the franchise business model that’s being adopted by a CDMO start-up.
• The continued growth of the sterile manufacturing space in North America and several growth drivers.
• Life as a founder of a CDMO start-up after 25+ years as a senior industry exec.

Cory has spent 25 years in the CDMO space. After a spell with Baxter, he served as vice president of business development and marketing for Cook Pharmica until its 2017 sale to Catalent for $950M. He has since founded INCOG, a start-up CDMO that is investing $60M to build its 90,000 square foot headquarters in Fishers, Indiana and hiring about 150 people by the end of 2024.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

From Big Pharma to CDMO leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Louise Duffy, Ph.D., SVP and Head of the Scientific Project Leaders at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Louise, covering:

• Learnings for CDMOs after almost three decades spent with big pharma. 
• How to balance the juggling act between dealing with hundreds of projects, clients, and systems as a fast-growing large molecule CDMO.
• Why the speed of innovation has massively increased in pharma and biopharma over the last 10 years.
• Tips on how to improve your presence and move forward quicker as a female leader.
• The importance of closer-knit supply chains involving originators, CDMO, technology, equipment, and material providers in developing increasingly complex molecules.
• The trend towards customised molecules with exquisite targeting and greater government interest as consequence of Covid.

Dr. Louise Duffy is a Senior Executive with an extensive background in the global bio/pharmaceutical industry with experience in business development, strategy, R&D, operations, and supply chain. She has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. With broad CMC and regulatory experience and specialist knowledge in personalised medicine, biochemical engineering, chemistry, and biological sciences Louise is SVP and Head of the Scientific Project Leaders at Abzena.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The change optimist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sébastien Ribault, Vice President & Head of End to End CDMO Services, Process Solutions at Merck Life Science.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sébastien, covering:

• The ever-changing world of biotech and how things talked about 20 years ago are now becoming a reality for many treatments. 
• Re-inventing the drug development process when faced with the 'Everest' of taking a covid treatment from bench to production in just nine months. 
• Learning to ask those around you: "If you could do things differently - what would you do?" as a way of unlocking innovation and challenging the norm.
• The wave of personalised medicines and treatments on the horizon and the need to develop the tools to bring down costs and make them more accessible.

With a PHD in Molecular & Cellular Biology, Sébastien has been in the biotech space for almost 25 years. He has spent the bulk of his career at Merck Life Science where he has progressed to the position of Head of End to End CDMO Services for Process Solutions.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! 

Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile, and generate leads in life sciences.

 

The Public Health vaccine specialist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vanessa Elharrar  PPD, VP, Vaccines Business Strategy Lead, at PPD Vaccine Clinical Development and Medical Affairs.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vanessa, covering:  

• Being at the centre of vaccine development and patient distribution over the last year. And the global pandemic’s role as a day of reckoning for the sector to do things differently in terms of virtualisation of trials becoming the norm.
• How MRNA vaccines could be the key to helping in HIV research and supporting patients at risk of AIDS.
• Carving a career path aimed at making the biggest impact on the global patient population.
• The need to be better prepared for future pandemics in terms of better better disease surveillance and detection, but also stockpiling vital equipment and having local vaccine manufacturing capability.
• The increasing trend towards CDMOs and CROs merging to offer a complementary and unified offering to help clients reduce timelines.

An MD/Doctor by trade, Vanessa now leads early engagement with Vaccine sponsors and offers strategic guidance in the development and implementation of vaccine trials. Her areas of expertise include COVID-19 vaccine development and medical monitoring of vaccine studies and HIV biomedical prevention. She is Board Certified in Preventive Medicine and Public Health having completed a Masters in Public Health at The John Hopkins University. If that was not impressive enough, Vanessa is also fluent in French, Spanish and Hebrew.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The academic turned biopharma innovator

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with JaeB Kim, Managing Director at Samsung Biologics America.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with JaeB, covering:

• A year at one of the largest and fastest-growing CDMOs in the world.
• Growing a US presence within the thriving biopharma cluster in San Francisco Bay with ambitious plans for future expansion.
• The need for industry to ‘give’ in order to ‘take’ from innovation in academia, along with the pivotal role that collaboration has played during the pandemic.
• How Covid-19 has ‘tested the system’ from R&D to logistics and patient supply and how this will enable the sector to be better prepared for a more orchestrated response to future pandemics.

JaeB is a senior life sciences professional with 15 years of experience in biotech and biologics manufacturing. With an MBA and a PhD in Cancer Biology, he worked for PerkinElmer before joining global CDMO giant Samsung Biologics in 2020. JaeB is also an Adjunct Assistant Professor at Michigan State University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

From chemist to consultant

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Urvish Pandya, Managing Director at Allotrope Scientific Ltd.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Urvish, covering:

• The exponential growth of chemistry in India leading to the production of many fine Indian chemists all over the world.
• Honest advice on how to deal with being made redundant as a result of being caught in the crossfire of M&A in the outsourcing space.
• The role of guiding drug sponsors in finding the right CRO and CDMO match, then getting the best out of them as a partner.
• The need for more modular and flexible capabilities in later stages of the drug manufacturing process.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The unique general

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andrew Moore, General Manager at Pfizer CentreOne.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrew, covering:

• The pride of being part of Pfizer in the last year and first-hand experience of working with CEO Albert Bourla.
• Lifelong leadership lessons learnt during eight years of military service in Iraq, where decisions cost lives.
• Being the only black guy in the room 99% of the time and the seriousness of being a black leader and the need to drive diversity for better business outcomes.
• Pushing yourself outside of your comfort zone by going from the corporate life to a ‘roll your sleeves up’ CEO at a university spin-out.

Andrew is an experienced healthcare leader and entrepreneur, who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles Baxter, AmerisourceBergen and McKesson. Most recently Andrew was the CEO of AI start-up CogxVision before rejoining Pfizer. Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Stickability factor

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Moody, Vice President of Technology Development and Commercialisation at Almac.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• 20 years at Almac and being on a journey that has seen the company go from a few hundred staff to over 5500 people.
• The chemistry of today is not the chemistry of tomorrow, including the future impact of flow chemistry and the need to bring new technologies together.
• The importance of giving back to the community and inspiring the next generation of scientists.
• Reinventing yourself as a way to keep you on your toes

Prof. Tom Moody is the Vice President of Technology Development and Commercialisation at Almac Sciences. His work has earned him numerous accolades and he is co-author and author of over 60 publications and patents. He is a strategic leader and technical expert in chiral chemistry and biocatalysis with more than 20 years of extensive academic and industry experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.